Skip to main content
Fig. 1 | Experimental Hematology & Oncology

Fig. 1

From: Leukemogenic SHP2 mutations lead to erythropoietin independency of HCD-57 cells: a novel model for preclinical research of SHP2-mutant JMML

Fig. 1

Expression of SHP2-D61Y and -E76K leads to cytokine-independent survival and proliferation in HCD-57 cells with the activation of the MAPK signaling pathway. A Number of live cells, GFP-positive cells, and the percentage of GFP-positive cells in live cells analyzed by flow cytometry of HCD-57 cells expressing SHP2-D61Y, SHP2-E76K or wild-type SHP2 in the absence of EPO. B, C Percentage of apoptotic cells (Annexin V-positive) in sorted GFP + HCD-57 cells cultured with or without EPO. D, E Percentage of apoptotic cells (Annexin V-positive) in sorted GFP + Ba/F3 cells cultured with or without IL-3. The error bar denotes the standard deviation. F Immunoblot analysis of pSHP2 (Tyr542), SHP2, pERK (Tyr202/204) and ERK in parental HCD-57 cells and HCD-57 cells expressing SHP2, SHP2-D61Y or E76K cultured with or without EPO. G Venn diagram indicating the overlapping upregulated genes in HCD-57 vs. SHP2-D61Y and HCD-57 vs. SHP2-E76K. H KEGG analysis of the shared upregulated genes in HCD-57 cells expressing SHP2-D61Y or -E76K compared with parental cells. The signal transduction pathways are summarized. I GSEA plots of MAPK signaling pathway target genes in HCD-57 cells expressing SHP2-D61Y or -E76K vs. parental cells. Normalized ES (NES), nominal p value and FDR q-values are indicated. J Heatmap of representative differentially expressed genes involved in the MAPK signaling pathway

Back to article page